US Bancorp DE Has $56,000 Holdings in Innoviva, Inc. (NASDAQ:INVA)

US Bancorp DE boosted its holdings in Innoviva, Inc. (NASDAQ:INVA) by 24.5% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 2,875 shares of the biotechnology company’s stock after buying an additional 566 shares during the period. US Bancorp DE’s holdings in Innoviva were worth $56,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently modified their holdings of the stock. GAMMA Investing LLC increased its stake in shares of Innoviva by 18.5% during the third quarter. GAMMA Investing LLC now owns 4,119 shares of the biotechnology company’s stock worth $80,000 after purchasing an additional 643 shares during the period. ProShare Advisors LLC boosted its holdings in shares of Innoviva by 6.2% in the 1st quarter. ProShare Advisors LLC now owns 16,150 shares of the biotechnology company’s stock valued at $246,000 after purchasing an additional 942 shares in the last quarter. SummerHaven Investment Management LLC increased its holdings in shares of Innoviva by 1.7% during the second quarter. SummerHaven Investment Management LLC now owns 59,853 shares of the biotechnology company’s stock worth $982,000 after buying an additional 980 shares in the last quarter. Evergreen Capital Management LLC raised its position in Innoviva by 10.9% in the second quarter. Evergreen Capital Management LLC now owns 12,321 shares of the biotechnology company’s stock valued at $202,000 after purchasing an additional 1,209 shares during the last quarter. Finally, Bessemer Group Inc. raised its holdings in Innoviva by 333.5% in the 1st quarter. Bessemer Group Inc. now owns 2,211 shares of the biotechnology company’s stock valued at $33,000 after buying an additional 1,701 shares during the last quarter. 99.12% of the stock is owned by institutional investors.

Innoviva Trading Down 1.8 %

Shares of INVA stock opened at $18.90 on Monday. The company has a debt-to-equity ratio of 0.38, a current ratio of 1.79 and a quick ratio of 1.64. The business has a 50-day moving average of $19.64 and a 200 day moving average of $17.99. The stock has a market capitalization of $1.18 billion, a PE ratio of 27.39 and a beta of 0.57. Innoviva, Inc. has a 1-year low of $13.41 and a 1-year high of $21.28.

Innoviva (NASDAQ:INVA) last announced its quarterly earnings results on Wednesday, November 6th. The biotechnology company reported $0.02 earnings per share for the quarter, missing the consensus estimate of $0.27 by ($0.25). The firm had revenue of $89.51 million for the quarter. Innoviva had a net margin of 18.31% and a return on equity of 20.84%. As a group, sell-side analysts anticipate that Innoviva, Inc. will post 0.33 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of brokerages have commented on INVA. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Innoviva in a research report on Tuesday, July 30th. StockNews.com lowered Innoviva from a “strong-buy” rating to a “buy” rating in a report on Tuesday, August 6th.

About Innoviva

Innoviva, Inc engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company’s products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia.